诚志股份（000990.SZ）1月29日在投资者互动平台表示，美国BLS子公司RIAGEV新产品系列以及 NAD+产品的销售网络覆盖欧洲、美洲、亚洲等全球主要国家和地区。2025年，相关产品的推广工作顺 利，在欧美以及亚洲的销售额持续增加。在生命医疗领域，公司将持续加强合成生物领域应用研究的投 入，不断延伸产业链条，丰富产品结构，提升品牌价值，构建更具综合竞争实力的合成生物业务板块。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贵公司子公司美国 BLS 公司相关产品应用开发方面处 于国际领先地位， 拥有全球范围内的销售网络，请问是否销售网络涉及欧盟成员国？ ...

Core Viewpoint - The Shandong Provincial Political Consultative Conference is focusing on expanding domestic demand, enhancing consumption potential, and improving the modern industrial system to ensure a strong start for the 14th Five-Year Plan [2][3]. Group 1: Economic Development Strategies - The light industry is identified as a key driver for expanding domestic demand and promoting consumption, with a focus on increasing product variety, quality, and brand creation [3]. - The private economy is emphasized as a backbone of the economy, with private entrepreneurs encouraged to take the lead in driving development [3]. - Traditional industries are urged to undergo transformation and upgrading, leveraging successful experiences from sectors like wood processing to enhance value and efficiency [3]. Group 2: Innovation and Technology - The development of a deep-sea industry system is proposed, utilizing technology and talent to transform the ocean into a strategic space for high-quality development [4]. - Shandong is encouraged to become a hub for synthetic biology innovation, focusing on high-end, intelligent, and green industrial development [4]. - The province is advised to capitalize on the second quantum revolution by enhancing research and application in quantum technology [4]. Group 3: Health and Agriculture - The health industry is recognized as a significant growth area, with recommendations to integrate AI and healthcare to expand high-end health consumption [4]. - Financial services are suggested to be embedded in the rural industrial upgrade chain to support agricultural development [5]. - Enhancements in agricultural emergency capabilities and insurance systems are recommended to ensure production safety [6]. Group 4: Urban and Social Development - The need for resilient cities is highlighted, with calls for improved monitoring and crisis response capabilities [6]. - The importance of expanding rehabilitation and nursing services for the elderly is emphasized, addressing the challenges faced by healthcare institutions [7]. - The potential of sports to enhance public health and stimulate consumption is recognized, with suggestions to leverage the success of major sports events [7]. Group 5: Overall Contributions - A total of 164 proposals were submitted during the conference, reflecting the commitment of committee members to support development and serve the public [7].

Group 1: Core Development Goals - The "14th Five-Year" period has seen significant progress in cultural initiatives, enhancing public cultural services for citizens [3] - The "15th Five-Year" plan aims to establish Beijing as a historical and cultural city, focusing on the protection and management of cultural heritage [4][5] - The plan emphasizes the integration of culture, commerce, tourism, and sports to create a comprehensive consumption experience [3] Group 2: Economic and Infrastructure Development - The fixed asset investment target for this year is set to exceed 1 trillion yuan, with a focus on strategic projects and infrastructure improvements [6][7] - Major projects include the implementation of significant industrial and infrastructure initiatives to enhance modern capabilities and public services [7] - The plan includes the establishment of a talent allocation mechanism to support core technology development and innovation [8][9] Group 3: Environmental and Health Initiatives - The "15th Five-Year" period will focus on achieving advanced carbon efficiency levels and improving ecological environments [10][11] - Measures will be taken to enhance the healthcare system, including the establishment of a tiered medical service system and improved access to healthcare resources [13] - The plan aims to promote green and low-carbon transitions in economic and social development [11] Group 4: Housing and Urban Development - The plan includes initiatives for urban renewal, such as the renovation of old elevators and the construction of accessible community spaces [12] - Housing policies will be improved to ensure better living conditions for new citizens and young people, with a focus on rental housing [12] - The goal is to transition from "housing for all" to "housing for livability," enhancing urban living quality [12]

Core Viewpoint - Fujian Pharmaceutical is experiencing significant operational improvement in 2025, driven primarily by its lithium battery electrolyte additive business, which has benefited from rising demand in the power battery and energy storage markets [1][5]. Group 1: Business Performance - The lithium battery electrolyte additive products, such as VC and FEC, saw a substantial price increase in Q4 2025, with battery-grade VC averaging 164,000 yuan/ton, up over 200% from the low in September [1]. - The pharmaceutical manufacturing segment has optimized steadily despite intense market competition, with a decrease in the price of key raw materials like 6-APA, leading to an improvement in gross margins [1][2]. - The company reported a net loss of 39 million to 57 million yuan for the year, marking a significant reduction in losses, and achieved profitability in Q4, indicating a positive trend in operational performance [5]. Group 2: Future Outlook - The synthetic biological microbial protein business achieved critical breakthroughs in 2025, obtaining multiple certifications that pave the way for large-scale production, although its contribution to 2025's performance is limited [3]. - For 2026, the company plans to consolidate its market position in pharmaceuticals, leverage price increases in the new energy sector, and accelerate the development of the microbial protein project to enhance capacity and market presence [3].

Core Viewpoint - Fuxiang Pharmaceutical is expected to significantly reduce its net loss in 2025, projecting a loss of 39 million to 57 million yuan, with a potential turnaround to profitability in Q4, driven by the synergy of its three main business segments: new energy, pharmaceutical manufacturing, and synthetic biology [1] Group 1: Business Performance - The new energy lithium battery electrolyte additive business is identified as the core driver of performance growth in 2025, benefiting from rising demand in the power battery and energy storage markets, leading to a substantial price increase for products like VC and FEC in Q4 [1] - The pharmaceutical manufacturing segment has optimized its operations despite intense market competition, with a decrease in the price of key raw materials like 6-APA alleviating cost pressures and improving gross margins [2] - The synthetic biology segment achieved significant milestones in 2025, obtaining key certifications that enable the transition from laboratory research to large-scale production, indicating a successful compliance pathway [2] Group 2: Future Outlook - For 2026, the company aims to consolidate its market position in the pharmaceutical sector while focusing on cost reduction and efficiency improvements [3] - The company plans to capitalize on the rising product prices in the new energy sector by enhancing production capacity through technological upgrades [3] - The company will accelerate the development of the synthetic biology protein project, expanding its application scenarios and enhancing its market presence both domestically and internationally [3]

Group 1 - The core point of the article is that Jinbo Bio has received approval from the China Securities Regulatory Commission (CSRC) for a targeted stock issuance, marking the first such approval for the Beijing Stock Exchange in 2024, which is expected to enhance the refinancing system for companies listed on the exchange [1][3] - Jinbo Bio plans to issue up to 7.1757 million shares, aiming to raise no more than 2 billion yuan, with the funds primarily directed towards the development of an AI research platform [1][2] - The strategic investor, Yangshengtang, is expected to help Jinbo Bio overcome development bottlenecks and stimulate the upstream and downstream enterprises in the industry chain [1] Group 2 - The funds raised will focus on the "Humanized Collagen FAST Database and Product Development Platform Project," which utilizes the company's self-developed "AI Collagen Brain System" technology to enhance efficiency in the development of humanized collagen [2] - The Beijing Stock Exchange has established a flexible and diverse refinancing mechanism since its inception, with the current focus on targeted convertible bonds and stock issuance, as evidenced by Jinbo Bio's successful registration [3] - The successful implementation of Jinbo Bio's stock issuance is expected to increase overall market attention on companies listed on the Beijing Stock Exchange, attracting various long-term funds and enhancing market liquidity [4]

Core Viewpoint - Ningbo aims to enhance its manufacturing sector by targeting the addition of 15 national-level manufacturing champions and 60 specialized and innovative "little giant" enterprises by 2026 [1] Group 1: Current Achievements - Ningbo currently has 119 "single champion" enterprises, maintaining the top position among cities in China for eight consecutive years [3][11] - The city's industrial added value has risen from ninth to fifth among national cities, while the number of high-tech enterprises has increased from 3,102 to over 10,000, marking a growth rate that has led the province for four consecutive years [3][11] Group 2: Future Goals - The government report outlines key tasks for the next five years, emphasizing the strengthening of industrial clusters and the foundation of the real economy, with a focus on building a global advanced manufacturing hub [5][13] - Ningbo aims for its industrial added value to exceed 1 trillion yuan, with strategic emerging industries expected to account for over 35% of the total [5][13] Group 3: Innovation and Development - The city plans to enhance its R&D intensity to over 3.6% during the 14th Five-Year Plan period, establishing a nationally influential industrial technology innovation center [7][15] - Initiatives include the creation of high-quality concept verification centers and shared manufacturing platforms to foster a unique "tropical rainforest" innovation ecosystem [7][15] Group 4: Policy Support - Ningbo has established a "Big Manufacturing" task force to support high-quality development in manufacturing through a comprehensive policy framework, including financial incentives for emerging industries and robotics projects [9][17] - The city is committed to optimizing investment mechanisms to facilitate the transformation of national technological achievements and support local enterprise expansion [9][17]

运河明珠 2025年8月，小河公园跨运河人行桥开放 5栋高层建筑与4栋多层建筑巧妙组合，内部空间设计灵活，可根据需求自由组合，满足不同使用模 式的切换……这便是位于拱墅区智慧网谷小镇核心区域的国贸云商数字商贸总部基地，于去年完工投 用。该总部基地紧密围绕健康医药和数字经济两大核心领域，打造浙江省国贸健康产业的旗舰典范和数 字医疗的区域标杆，推动拱墅大城北区域转型升级步伐进一步加快。 大运河杭钢公园 汇金云创·科创人才综合体 朝霞刚刚浸染云层，拱墅大城北的产业脉搏已强劲跃动。智慧园区中，智能机器人正沿着预定轨迹 自如巡检；数据中心的屏幕墙上，实时跳动的工业互联网信号连接着千里外的生产线；而在新建的智造 车间，柔性产线已悄然切换工序，精密机械臂于寂静中勾勒出智能制造的韵律。 瞄定"打造大运河保护传承利用的经典范例、超大城市有机更新的示范样板、杭州高质量发展的新 增长极"目标，杭州大城北建设，已步入了关键阶段。 2025年，拱墅区共计实施大城北建设项目77个，开工率达107%，完工率达123%，年度投资超70亿 元。基建日益完善下，拱墅以产业蝶变为核心引擎，同步推进交通路网升级、民生服务提质，全方位构 建"产城人文 ...

一旁的同创伟业合伙人张鹏也提到："我们和常德2022-2023年开始基金层面合作，最初没料到内地城市 能有这么好的营商环境。"他笑称，常德政府的办事效率和领导风格"更像沿海地区"，这种超预期的体 验让企业落地格外顺畅。双方合作的一期基金基本完成了投资工作，现在开始筹备规模更大的二期基 金，已经落地的项目中有两家实现了一年内营收从0破千万。 投资机构纷至沓来 以前的常德，桃花源的田园诗意与"芙蓉王"铸就的工业传奇是它的城市标签。这座曾长期依赖烟草产业 的城市，在最近的几年内竟悄然崛起为合成生物产业高地，成为全国重要的甾体原料药和中间体生产出 口基地。 "常德做合成生物学为什么相对成功？它不是跟风的。"在大赛间隙的交流中，东方富海合伙人陈华伟很 认真地表示。他指出，常德在合成生物学领域的布局并非追逐热点，而是在2022年前后，在全国范围内 与合成生物学方向的院士专家、投资机构的系统调研和内部多次培训后，结合本地资源禀赋做出的战略 决策。 基于常德独有的产业基础，才有了之后的快速发展。据他介绍，常德在传统生物发酵领域本身拥有基 础，例如作为全国重要的培养基基地，为产业发展提供了独特的人才和要素支撑。 目前，东方富海 ...

Financing Overview - From January 12 to January 18, Shanghai enterprises experienced 24 financing events, with 15 disclosing financing amounts, totaling 2.8485 billion yuan [2] - The number of financing events remained the same as the previous week, with the highest number occurring in the Pudong New Area, which had 7 events [2] Artificial Intelligence - SenseTime Medical completed nearly 100 million yuan in strategic financing on January 12, with investment from Henan Huirong Fund [4] - Wuzhitai Technology, a robot leasing platform, secured several tens of millions in Pre-A round financing on January 15, with investments from Lion City Capital, Baidu Investment, and existing shareholder Jingya Capital [5] - Qingtian Rental, another robot leasing platform, completed seed round financing on January 15, led by Hillhouse Venture Capital and supported by several other investors [6] - Futuring Robotics, focusing on dual-arm household service robots, raised 200 million yuan in angel round financing on January 12, with investments from ZhenFund, Yuanlai Capital, and Lianxin Capital [7] Integrated Circuits - Zhanwang Technology, an IC design company, completed 100 million yuan in angel round financing on January 14, led by Zijin Port Investment and金沙江联合资本 [8] - Lijiao Technology, specializing in semiconductor RF and plasma systems, completed Pre-A+ round financing on January 14, with investments from Shangrong Capital, Zhongbi Fund, and Shanghai Dingyu [9] - Yunshen Technology, focusing on semiconductor materials and equipment, completed A round financing on January 14, with investment from Yida Capital [10] Biomedicine - Yuanqi Bio, specializing in tumor immunotherapy, completed 70 million USD in C round financing on January 12, led by Beijing Pharmaceutical Health Industry Investment Fund and QIA [11] - Fanfang Medical, focusing on medical devices, completed angel round financing on January 12, with investment from Tianshi Innovation Capital [12] - Ailios, specializing in pharmaceutical process filtration, completed over 100 million yuan in Pre-B round financing on January 15, led by Guotou Chuanghe [13] - Xinyao Paike, focusing on drug packaging materials and medical devices, completed 100 million yuan in B+ round financing on January 15, led by Guangfa Xinde [14] - Shengshengji, specializing in precision intelligent health technology, completed several tens of millions in angel financing on January 15 [15] Future Industries - Shuli Innovation, focusing on brain-machine interfaces, completed several hundred million yuan in B+ round financing on January 16, with investments from the National SME Development Fund and Dongfang Fuhai [16] - Jinghai Weixiang, specializing in synthetic biology, completed nearly 100 million yuan in B round financing on January 12, with investment from Jiazhizhi Fund [17] - Huanliang Technology, focusing on AI new materials, completed strategic financing on January 13, with investment from Qicai Chemical [18] - Jingxiang Technology, specializing in flexible tactile sensors, completed angel round financing on January 14, with investments from Zhongke Chuangxing and Pudong Fund [19] - Xinhang Micro, focusing on vacuum components, completed several tens of millions in angel round financing on January 12, with investments from Yushan Capital and Daohua Investment [20] - Youji Technology, specializing in machine tool intelligence, completed B round financing on January 14, with investment from Changyingxin Investment [21] - Xinghuan Juneng, focusing on fusion energy commercialization, completed 1 billion yuan in A round financing on January 12, with investments from multiple institutions [22] - Chaomagnet New Energy, specializing in high-temperature superconducting strong field magnets, completed several hundred million yuan in angel round financing on January 16, led by Dingfeng Chuangke [23]